Executive

TEAM

Paradigm’s leadership team is highly experienced in scientific discovery, regulatory affairs, drug development, clinical trials, finance, and investor relations, as well as licensing and commercialisation.

They are genuinely ‘experts in uncovering the real value of a molecule’.

Sharing a belief in transforming medicine and its potential to open up new treatment options for people around the globe, the team’s strategic plan centres upon ensuring Paradigm grows and fosters the knowledge, talent, experience and creativity necessary for long term success.

They lead by example in shaping a company culture that supports Paradigm’s Purpose and Vision.

PAUL RENNIE
MANAGING DIRECTOR

Mr Rennie is recognised as a leading authority in drug development and has been involved in a number of pre-clinical and clinical trial programs over his accomplished career. He was the inaugural COO of Mesoblast and most recently as Executive VP, New Product Development at Mesoblast Ltd. Mr. Rennie has extensive experience in commercialising Intellectual Property.

PAUL RENNIE
MANAGING DIRECTOR

Mr Rennie is recognised as a leading authority in drug development and has been involved in a number of pre-clinical and clinical trial programs over his accomplished career. He was the inaugural COO of Mesoblast and most recently as Executive VP, New Product Development at Mesoblast Ltd. Mr. Rennie has extensive experience in commercialising Intellectual Property.

Dr Donna Skerrett
Chief Medical Officer

Dr. Skerrett, has more than 30 years’ experience in transfusion medicine,
cellular therapy, and regenerative medicine. She was the CMO of Mesoblast, a
stem cell development company, from 2011-19; Dir. Transfusion Medicine &
Cellular Therapy at Weill Cornell Medical Center, NY from 2004-11; and Ass.
Dir. Transfusion Medicine at Columbia University’s NY-Presbyterian Hospital.
She has chaired the NY State Governor’s Council on Blood and Transfusion
Service and served on the Board of Directors of the Fox Chase Cancer Center.
She currently serves in an advisory role on the Board of Visitors for the Lewis
Katz School of Medicine of Temple University.

Dr Donna Skerrett
Chief Medical Officer

Dr. Skerrett, has more than 30 years’ experience in transfusion medicine, cellular therapy, and regenerative medicine. She was the CMO of Mesoblast, a stem cell development company, from 2011-19; Dir. Transfusion Medicine & Cellular Therapy at Weill Cornell Medical Center, NY from 2004-11; and Ass. Dir. Transfusion Medicine at Columbia University’s NY-Presbyterian Hospital. She has chaired the NY State Governor’s Council on Blood and Transfusion Service and served on the Board of Directors of the Fox Chase Cancer Center. She currently serves in an advisory role on the Board of Visitors for the Lewis Katz School of Medicine of Temple University.

Abby Macnish Niven
CFO and Company Secretary

After a career spent in private wealth management with groups such as ANZ, UBS and Ord Minnett, Abby now consults to various companies, both listed and unlisted, in the areas of governance, finance and corporate structure. Abby holds Bachelor of Commerce and Bachelor of Science degrees from UWA and is a Chartered Financial Analyst. 

Amongst her consulting roles, Abby is also CFO & Company Secretary for ASX listed companies Tombador Iron Ltd and NeuroScientific Biopharmaceuticals Ltd and also serves as a board member of Neuromuscular WA.

Abby Macnish Niven
CFO and Company Secretary

After a career spent in private wealth management with groups such as ANZ, UBS and Ord Minnett, Abby now consults to various companies, both listed and unlisted, in the areas of governance, finance and corporate structure. Abby holds Bachelor of Commerce and Bachelor of Science degrees from UWA and is a Chartered Financial Analyst. 

Amongst her consulting roles, Abby is also CFO & Company Secretary for ASX listed companies Tombador Iron Ltd and NeuroScientific Biopharmaceuticals Ltd and also serves as a board member of Neuromuscular WA.

Dr Ravi Krishnan
Chief Scientific Officer

Dr Krishnan is a basic scientist with a long-standing interest and experience in experimental pathology, transplantation immunology, gene and stem cell
therapy. He has had significant experience in investigating novel compounds with immune modulatory effects, anti-inflammatory and anti-angiogenic
properties.

Dr Ravi Krishnan
Chief Scientific Officer

Dr Krishnan is a basic scientist with a long-standing interest and experience in experimental pathology, transplantation immunology, gene and stem cell therapy. He has had significant experience in investigating novel compounds with immune modulatory effects, anti-inflammatory and anti-angiogenic properties.

Dr Karla Knower
Regulatory Affairs

An accomplished Regulatory Affairs professional whose career includes experience at Medical Developments International, Starpharma, and Mesoblast. Dr. Knower has extensive experience driving global regulatory strategies for diverse product portfolios for pharmaceuticals, devices, drug-devices, and stem cell therapies. Dr. Knower’s comprehensive understanding of the drug development process drives careful and thoughtful consideration at every step to maximise regulatory growth.

Dr Karla Knower
Regulatory Affairs

An accomplished Regulatory Affairs professional whose career includes experience at Medical Developments International, Starpharma, and Mesoblast. Dr Knower has extensive experience driving global regulatory strategies for diverse product portfolios for pharmaceuticals, devices, drug-devices, and stem cell therapies. Dr. Knower’s comprehensive understanding of the drug development process drives careful and thoughtful consideration at every step to maximise regulatory growth.

Simon White
Director of Investor Relations

Mr White brings a unique set of skills to his role. His career to date combines
experience in equity capital markets and the financial services sector (gained
as Corporate Advisory at DELCOR, a Melbourne based Family Office, and
Institutional Sales at Sequoia Wealth Management) with time as a high-
performance athlete (he was a professional footballer for the AFL team,
Carlton, for 8 years). His team-orientated approach and networking skills are
highly valued.

Simon White
Director of Investor Relations

Mr White brings a unique set of skills to his role. His career to date combines experience in equity capital markets and the financial services sector (gained as Corporate Advisory at DELCOR, a Melbourne based Family Office, and Institutional Sales at Sequoia Wealth Management) with time as a high- performance athlete (he was a professional footballer for the AFL team, Carlton, for 8 years). His team-orientated approach and networking skills are highly valued.

Samantha Williams
Director of Business Operations

Samantha Williams came to Paradigm with a wealth of local and international commercial and operational experience. Having founded and grown a successful company, she excels in tackling and solving complex challenges and uses critical insights to drive targeted growth. 

Throughout her career, Samantha has continued to build on a deep understanding of diverse cultures and their impact on overall business success. At Paradigm, she creates collaborative work environments, fostering strong relationships, and inspires teams to reach their full potential. With a proven track record in optimising operational efficiency and navigating complex business landscapes, Paradigm gains a valuable dynamic leader and culturally adaptable strategist.

Samantha Williams
Director of Business Operations

Samantha Williams came to Paradigm with a wealth of local and international commercial and operational experience. Having founded and grown a successful company, she excels in tackling and solving complex challenges and uses critical insights to drive targeted growth. 

Throughout her career, Samantha has continued to build on a deep understanding of diverse cultures and their impact on overall business success. At Paradigm, she creates collaborative work environments, fostering strong relationships, and inspires teams to reach their full potential. With a proven track record in optimising operational efficiency and navigating complex business landscapes, Paradigm gains a valuable dynamic leader and culturally adaptable strategist.